Forvis Mazars Wealth Advisors’s Elevance Health ELV Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$2.74M Sell
7,096
-5
-0.1% -$1.85K 0.05% 132
2026
Q1
$2.08M Sell
7,101
-8
-0.1% -$2.63K 0.04% 154
2025
Q4
$2.49M Sell
7,109
-677
-9% -$229K 0.05% 137
2025
Q3
$2.52M Sell
7,786
-250
-3% -$77.8K 0.05% 134
2025
Q2
$3.13M Buy
8,036
+47
+0.6% +$18.9K 0.07% 119
2025
Q1
$3.48M Sell
7,989
-43
-0.5% -$17.3K 0.08% 112
2024
Q4
$2.96M Sell
8,032
-409
-5% -$171K 0.07% 133
2024
Q3
$4.39M Buy
8,441
+109
+1% +$58.2K 0.1% 102
2024
Q2
$4.51M Buy
8,332
+56
+0.7% +$29.6K 0.11% 96
2024
Q1
$4.29M Sell
8,276
-314
-4% -$156K 0.11% 99
2023
Q4
$4.05M Sell
8,590
-539
-6% -$249K 0.11% 98
2023
Q3
$3.97M Sell
9,129
-188
-2% -$85.3K 0.12% 99
2023
Q2
$4.14M Sell
9,317
-266
-3% -$123K 0.12% 110
2023
Q1
$4.41M Sell
9,583
-148
-2% -$70.4K 0.14% 90
2022
Q4
$4.99M Sell
9,731
-1,051
-10% -$534K 0.17% 83
2022
Q3
$4.9M Sell
10,782
-266
-2% -$127K 0.2% 75
2022
Q2
$5.33M Buy
11,048
+3,112
+39% +$1.54M 0.22% 65
2022
Q1
$3.9M Buy
7,936
+266
+3% +$122K 0.17% 68
2021
Q4
$3.56M Sell
7,670
-121
-2% -$50.9K 0.15% 73
2021
Q3
$2.9M Sell
7,791
-210
-3% -$79.8K 0.13% 78
2021
Q2
$3.06M Sell
8,001
-749
-9% -$286K 0.14% 75
2021
Q1
$3.14M Sell
8,750
-875
-9% -$281K 0.16% 71
2020
Q4
$3.09M Buy
9,625
+462
+5% +$142K 0.15% 72
2020
Q3
$2.46M Sell
9,163
-105
-1% -$28.3K 0.14% 73
2020
Q2
$2.44M Sell
9,268
-879
-9% -$235K 0.16% 71
2020
Q1
$2.3M Sell
10,147
-73
-0.7% -$19.9K 0.19% 58
2019
Q4
$3.09M Buy
10,220
+86
+0.8% +$23.7K 0.22% 59
2019
Q3
$2.43M Sell
10,134
-137
-1% -$37.5K 0.19% 68
2019
Q2
$2.9M Sell
10,271
-210
-2% -$57.4K 0.23% 57
2019
Q1
$3.01M Buy
10,481
+92
+0.9% +$26.6K 0.25% 58
2018
Q4
$2.73M Sell
10,389
-485
-4% -$133K 0.28% 47
2018
Q3
$2.98M Sell
10,874
-352
-3% -$91.4K 0.26% 48
2018
Q2
$2.67M Buy
11,226
+77
+0.7% +$17.8K 0.26% 56
2018
Q1
$2.45M Sell
11,149
-374
-3% -$87.9K 0.25% 55
2017
Q4
$2.59M Sell
11,523
-391
-3% -$83.3K 0.26% 55
2017
Q3
$2.26M Sell
11,914
-678
-5% -$129K 0.25% 58
2017
Q2
$2.37M Sell
12,592
-442
-3% -$79.4K 0.27% 52
2017
Q1
$2.16M Buy
13,034
+509
+4% +$81K 0.26% 53
2016
Q4
$1.8M Buy
12,525
+869
+7% +$116K 0.24% 57
2016
Q3
$1.46M Buy
11,656
+1,089
+10% +$141K 0.2% 59
2016
Q2
$1.39M Sell
10,567
-141
-1% -$19.3K 0.21% 64
2016
Q1
$1.49M Buy
10,708
+150
+1% +$20K 0.24% 55
2015
Q4
$1.47M Buy
10,558
+63
+0.6% +$8.68K 0.22% 52
2015
Q3
$1.47M Sell
10,495
-1,862
-15% -$280K 0.26% 47
2015
Q2
$2.03M Sell
12,357
-308
-2% -$49.2K 0.3% 45
2015
Q1
$1.96M Sell
12,665
-341
-3% -$48.5K 0.28% 47
2014
Q4
$1.64M Sell
13,006
-192
-1% -$23.7K 0.27% 55
2014
Q3
$1.58M Sell
13,198
-176
-1% -$20.2K 0.27% 54
2014
Q2
$1.44M Sell
13,374
-2,055
-13% -$212K 0.25% 55
2014
Q1
$1.53M Sell
15,429
-90
-0.6% -$8.14K 0.27% 59
2013
Q4
$1.43M Sell
15,519
-780
-5% -$69.3K 0.27% 59
2013
Q3
$1.36M Buy
16,299
+43
+0.3% +$3.69K 0.28% 58
2013
Q2
$1.33M Buy
+16,256
New +$1.22M 1.05% 38

Other funds holding ELV

Forvis Mazars Wealth Advisors's ELV Position: Q2 2026 in Review

Forvis Mazars Wealth Advisors reduced its Elevance Health (ELV) stake by 0.07% in Q2 2026, selling an estimated $1.85K and leaving 7,096 shares worth $2.74M. The position accounts for 0.05% of the portfolio, ranked #132.

Forvis Mazars Wealth Advisors first reported a position in ELV in Q2 2013 and has held it in 53 quarters since. The position peaked at $5.33M in Q2 2022. 1,600 funds tracked by Wall St. Rank hold ELV as of Q2 2026.

  • Forvis Mazars Wealth Advisors held 7,096 shares of Elevance Health worth $2.74M as of Q2 2026.
  • Forvis Mazars Wealth Advisors sold 5 Elevance Health shares in Q2 2026, an estimated $1.85K.
  • Elevance Health made up 0.05% of Forvis Mazars Wealth Advisors's portfolio in Q2 2026, its #132 holding.
  • Forvis Mazars Wealth Advisors first reported a position in Elevance Health in Q2 2013 and has held it in 53 quarters since.
  • Forvis Mazars Wealth Advisors's Elevance Health position peaked at $5.33M in Q2 2022.
  • 1,600 funds tracked by Wall St. Rank held Elevance Health as of Q2 2026.

Based on Forvis Mazars Wealth Advisors's 13F filing for Q2 2026, filed 10 Aug 2026.